Vycor Medical Q2 revenue up 22% to $496K; VBAS division drives growth with new international distribution

VYCOR MEDICAL INC

2025-Q2 EPS reported -$0.01 revenue$932,731

Q2 total revenue $496,353 (+22% YoY); Vycor Medical (VBAS) up 24% to $481,788, led by international markets.
GAAP operating profit Q2 $51,146; non-GAAP operating profit $84,481, up from $31,859 in Q2 2024.
Gross margin fell to 83% from 91% due to validation/shipping costs of new production and sales mix.
Entered new distribution agreements for France and Spain during H1 2025, targeting key international markets.
Two new peer-reviewed VBAS clinical papers published in Q2; total now 48. NovaVision study validates NeuroEyeCoach for home/clinic.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.